Galaxy Surfactants vs Atlassian Which Outperforms?

Galaxy Surfactants and Atlassian are two companies with vastly different focuses in the stock market. Galaxy Surfactants is a leading manufacturer of specialty chemicals used in personal care and home care products, while Atlassian is a software company known for its popular collaboration and productivity tools. Both companies have shown strong performances in the past, but investors looking for stability and growth may find Galaxy Surfactants a safer bet, while those seeking higher returns may lean towards Atlassian.

Galaxy Surfactants

Atlassian

Stock Price
Day Low₹2910.00
Day High₹3031.60
Year Low₹2247.00
Year High₹3370.00
Yearly Change49.98%
Revenue
Revenue Per Share₹1079.31
5 Year Revenue Growth0.39%
10 Year Revenue Growth1.24%
Profit
Gross Profit Margin0.27%
Operating Profit Margin0.10%
Net Profit Margin0.08%
Stock Price
Day Low$237.80
Day High$247.15
Year Low$135.29
Year High$258.69
Yearly Change91.21%
Revenue
Revenue Per Share$17.54
5 Year Revenue Growth2.65%
10 Year Revenue Growth18.39%
Profit
Gross Profit Margin0.81%
Operating Profit Margin-0.03%
Net Profit Margin-0.09%

Galaxy Surfactants

Atlassian

Financial Ratios
P/E ratio33.94
PEG ratio0.41
P/B ratio4.77
ROE14.54%
Payout ratio0.00%
Current ratio0.00
Quick ratio0.00
Cash ratio0.00
Dividend
Dividend Yield0.75%
5 Year Dividend Yield25.74%
10 Year Dividend Yield0.00%
Galaxy Surfactants Dividend History
Financial Ratios
P/E ratio-163.19
PEG ratio0.86
P/B ratio62.24
ROE-38.28%
Payout ratio0.00%
Current ratio1.18
Quick ratio1.18
Cash ratio0.84
Dividend
Dividend Yield-%
5 Year Dividend Yield0.00%
10 Year Dividend Yield0.00%
Atlassian Dividend History

Galaxy Surfactants or Atlassian?

When comparing Galaxy Surfactants and Atlassian, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Galaxy Surfactants and Atlassian.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Galaxy Surfactants has a dividend yield of 0.75%, while Atlassian has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Galaxy Surfactants reports a 5-year dividend growth of 25.74% year and a payout ratio of 0.00%. On the other hand, Atlassian reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Galaxy Surfactants P/E ratio at 33.94 and Atlassian's P/E ratio at -163.19. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Galaxy Surfactants P/B ratio is 4.77 while Atlassian's P/B ratio is 62.24.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Galaxy Surfactants has seen a 5-year revenue growth of 0.39%, while Atlassian's is 2.65%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Galaxy Surfactants's ROE at 14.54% and Atlassian's ROE at -38.28%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are ₹2910.00 for Galaxy Surfactants and $237.80 for Atlassian. Over the past year, Galaxy Surfactants's prices ranged from ₹2247.00 to ₹3370.00, with a yearly change of 49.98%. Atlassian's prices fluctuated between $135.29 and $258.69, with a yearly change of 91.21%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.

Comparision